ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 191,68
0,64%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. INmune Bio Inc (INMB)

  7. INmune Bio Inc (INMB) Actualités

INMB

INmune Bio (INMB)

INmune Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INMB
DateHeureSourceTitreSymboleSociété
09/05/202422h05GlobeNewswire Inc.INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateNASDAQ:INMBINmune Bio Inc
07/05/202414h00GlobeNewswire Inc.INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9NASDAQ:INMBINmune Bio Inc
30/04/202414h00GlobeNewswire Inc.INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsNASDAQ:INMBINmune Bio Inc
29/04/202414h00GlobeNewswire Inc.INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
25/04/202415h00GlobeNewswire Inc.INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:INMBINmune Bio Inc
23/04/202414h00GlobeNewswire Inc.INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayNASDAQ:INMBINmune Bio Inc
22/04/202414h00GlobeNewswire Inc.INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingNASDAQ:INMBINmune Bio Inc
08/04/202414h00GlobeNewswire Inc.INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024NASDAQ:INMBINmune Bio Inc
28/03/202421h01GlobeNewswire Inc.INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateNASDAQ:INMBINmune Bio Inc
26/03/202421h01GlobeNewswire Inc.INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28NASDAQ:INMBINmune Bio Inc
13/03/202413h00GlobeNewswire Inc.INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyNASDAQ:INMBINmune Bio Inc
05/03/202414h00GlobeNewswire Inc.INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™NASDAQ:INMBINmune Bio Inc
12/02/202415h00GlobeNewswire Inc.INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:INMBINmune Bio Inc
06/02/202415h00GlobeNewswire Inc.INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024NASDAQ:INMBINmune Bio Inc
30/01/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
30/01/202414h00GlobeNewswire Inc.INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease ProgramNASDAQ:INMBINmune Bio Inc
16/01/202414h30GlobeNewswire Inc.ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyNASDAQ:INMBINmune Bio Inc
02/01/202414h00GlobeNewswire Inc.INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
18/12/202322h05Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:INMBINmune Bio Inc
18/12/202322h01GlobeNewswire Inc.INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDANASDAQ:INMBINmune Bio Inc
29/11/202314h00GlobeNewswire Inc.INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer SymposiumNASDAQ:INMBINmune Bio Inc
27/11/202314h00GlobeNewswire Inc.INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s DiseaseNASDAQ:INMBINmune Bio Inc
15/11/202315h00GlobeNewswire Inc.INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in EuropeNASDAQ:INMBINmune Bio Inc
13/11/202317h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
01/11/202321h10GlobeNewswire Inc.INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business UpdateNASDAQ:INMBINmune Bio Inc
01/11/202321h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INMBINmune Bio Inc
31/10/202313h00GlobeNewswire Inc.INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search AuthorityNASDAQ:INMBINmune Bio Inc
30/10/202314h07GlobeNewswire Inc.INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPαNASDAQ:INMBINmune Bio Inc
17/10/202314h00GlobeNewswire Inc.INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNASDAQ:INMBINmune Bio Inc
16/10/202315h00GlobeNewswire Inc.INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1NASDAQ:INMBINmune Bio Inc
 Showing the most relevant articles for your search:NASDAQ:INMB

Dernières Valeurs Consultées

EU
PX1
CAC 40
EU
AI
Air Liquide
EU
ACA
Credit Agricole
EU
LR
Legrand
EU
RI
Pernod Ricard
EU
CS
Axa
EU
VIV
Vivendi
EU
ORA
Orange
NASDAQ
GOOGL
Alphabet
EU
SGO
Cie de SaintGobain
COIN
BTCUSD
Bitcoin
EU
VK
Vallourec
EU
CAP
Capgemini
NYSE
JPM
JP Morgan Chase
EU
BNP
BNP Paribas
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés